DPP4 and myocardial infarction: One of the cardiovascular outcome trials on DPP4 inhibitors that was also included in the meta-analysis by Sinha and Ghosal, SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus—Thrombolysis in Myocardial Infarction 53), demonstrated a significantly increased risk of hospitalisation for heart failure associated with saxagliptin compared to placebo (HR 1.27 (95% CI 1.07–1.51)) [19].